Pancreastatin has been shown to impair glucose-stimulated insulin secretion and induce insulin resistance (27), whereas catestatin appears to exert anti-obesity effects by enhancing lipid mobilization and leptin signaling (6). The gene discussed is INS; the disease is obesity disorder.